Ipsen's Dysport has received marketing authorization from Health Canada for use in aesthetic medicine in the region. A division of Valeant Pharmaceuticals named Medicis Aesthetics Canada will market Dysport in the region. Ipsen's group ...
Tags: Health, aesthetic medicine
Lithera has announced the treatment of first patient with LIPO-202 (Salmeterol Xinafoate for Injection) in the Phase IIb RESET trial. LIPO-202 is an injectable pharmaceutical designed to produce aesthetic reduction of subcutaneous ...
Tags: pharmaceutical, drug, medical